Bristol-Myers Squibb, Celgene likely to face longer US antitrust probe
Bristol-Myers Squibb’s plan to buy Celgene likely faces an extended US antitrust investigation, given the impact of the partial federal government shutdown and size of the deal. But a longer review...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch